Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Pfizer Inc. et al v. Watson Pharmaceuticals Inc. et al
Case Number:
1:10-cv-00357
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 30, 2013
Watson Can't Prove Rapamune Patent Invalid, Judge Says
A Delaware federal judge on Wednesday rejected Watson Pharmaceuticals Inc.'s claims that Pfizer Inc.'s patent for the organ rejection drug Rapamune was invalid, handing Pfizer a victory in its efforts to halt abbreviated new drug applications for generic versions of the drug.
-
February 06, 2012
Ranbaxy Exits Pfizer's Suit Over Generic Rapamune
Ranbaxy Laboratories Ltd. on Monday exited a patent infringement suit launched by Pfizer Inc. against it and Watson Pharmaceuticals Inc. in Delaware federal court in response to abbreviated new drug applications to introduce a generic version of the organ rejection drug Rapamune.